• Poster

Quality of Life and the Prevalence of Vasomotor Symptoms in a Population-Based Sample of Peri- and Post-Menopausal Women

Citation

Britt, D. M., Fehnel, S. E., Granger, A. L., Zhou, X., & Williams, R. (2005, October). Quality of Life and the Prevalence of Vasomotor Symptoms in a Population-Based Sample of Peri- and Post-Menopausal Women. Presented at 12th Annual Conference on the International Society for Quality of Life Research, San Francisco, CA.

Abstract

Aims: The current study estimates the prevalence of vasomotor
symptoms (VMS) and quality of life (QOL) among peri- and
post-menopausal women.

Methods: Participants were recruited from a Knowledge
Networks panel, the only online panel based on a random digit
dial sample of the full US population. Over 4,000 pre-, periand
post-menopausal women (n= 4,402) completed portions
of the web-based survey. Analyses are limited to the 3,135
peri- and post-menopausal participants meeting study criteria.
In addition to reporting VMS frequency, severity, and related
healthcare, respondents completed the Menopause-Specific
Quality of Life Questionnaire (MENQOL), a 29-item self-report
measure assessing the presence and bothersomeness of
menopausal symptoms.

Subjects were classified into 3 groups based on VMS in the
past month: 1) met FDA draft guidance (7 or more moderateto-
severe daily hot flashes/night sweats); 2) hot flashes/night
sweats but less than FDA draft guidance; or 3) no hot
flashes/night sweats.

Results: Mean age of the sample was 55.1 years. Over twothirds
of the sample (67%) reported any VMS within the past
month (59% reported daytime hot flashes, 55% reported night
sweats). Only 7% of the sample met FDA draft guidance.
MENQOL scores between the peri- and post-menopausal
groups did not dramatically differ. However, significant
differences in MENQOL total and subscale (Vasomotor,
Psychosocial, Physical, Sexual) scores were observed among
the 3 VMS groups, with both VMS groups reporting significantly
diminished QOL (p
Conclusions: The current study provides much-needed
prevalence estimates of VMS and their impact on QOL among
menopausal women. US regulatory draft guidance focuses on
women with 7 or more moderate-to-severe menopausal
symptoms per day. However, VMS significantly impact QOL
for a much larger portion of the peri- and post-menopausal
population.